No material financial or clinical catalyst here — this is a supply-chain readiness update. Watch for the Phase 2 ovarian cancer data readout and any subsequent regulatory interactions as the next real catalysts. The stock's $22M market cap means binary trial outcomes will drive volatility, not manufacturing timelines.
Price Chart
Executive Summary
Allarity Therapeutics announced that its Phase 3 API manufacturing campaign for stenoparib is on track for completion by Q3 2026, with all manufacturing payments already completed and no additional cash outlays anticipated. This is a routine operational update for a pre-revenue clinical-stage biotech — no new clinical data, financial results, or regulatory milestones were reported.
Key Facts
- Phase 3 API manufacturing campaign for stenoparib on track for completion no later than Q3 2026
- All manufacturing-related payments completed; no additional cash outlays for manufacturing anticipated
- CDMO site in Europe operates in full compliance with FDA and EMA GMP standards
- Manufacturing campaign expected to be completed ahead of critical data from ongoing Phase 2 trial in advanced ovarian cancer
- Company is a Phase 2 clinical-stage pharmaceutical company with no approved products or reported revenue
Financial Impact
No financial figures disclosed. All manufacturing payments completed with no additional cash outlays anticipated.
Risk Factors
- Manufacturing scale-up or regulatory compliance issues could delay pivotal trial start
- No guarantee of successful Phase 2 data or FDA approval for stenoparib
- Cash runway not disclosed; pre-revenue company may need additional financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-052542 |
| Document: ea0289243-8k_allarity.htm | 0001213900-26-052542 |
| Document: 0001213900-26-052542-index-headers.html | 0001213900-26-052542 |
| Document: 0001213900-26-052542-index.html | 0001213900-26-052542 |
| Document: 0001213900-26-052542.txt | 0001213900-26-052542 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $1.04 | awaiting T+20 | — | $0.9430 (−9.33%) |
Sep 29, 2026 28d ago | 8-K | $0.9651 | awaiting T+20 | — | $0.9430 (−2.29%) |
Sep 28, 2026 29d ago | Press Release | $0.9684 $0.9151 | ▼ −5.50% | ▼ −5.47% | $0.9430 (−2.62%) |
Sep 16, 2026 5w ago | 8-K | $1.16 $0.8699 | ▼ −24.68% | ▼ −27.86% | $0.9430 (−18.35%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $0.8601 | ▼ −26.49% | ▼ −28.75% | $0.9430 (−19.40%) |
Sep 11, 2026 6w ago | Press Release | $1.22 $0.9900 | ▼ −18.85% | ▼ −20.72% | $0.9430 (−22.70%) |
Aug 14, 2026 10w ago | Press Release | $1.37 $1.17 | ▼ −14.60% | ▼ −12.61% | $0.9430 (−31.17%) |
Jul 1, 2026 16w ago | 8-K | $1.33 $1.16 | ▼ −12.78% | ▼ −10.60% | $0.9430 (−29.10%) |
Jun 22, 2026 18w ago | 8-K | $1.36 $1.19 | ▼ −12.50% | ▼ −12.35% | $0.9430 (−30.66%) |
Jun 18, 2026 18w ago | Press Release | $1.43 $1.17 | ▼ −18.18% | ▼ −18.71% | $0.9430 (−34.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers